HRP970569B1 - Fharmaceutical compositions - Google Patents

Fharmaceutical compositions

Info

Publication number
HRP970569B1
HRP970569B1 HR970569A HRP970569A HRP970569B1 HR P970569 B1 HRP970569 B1 HR P970569B1 HR 970569 A HR970569 A HR 970569A HR P970569 A HRP970569 A HR P970569A HR P970569 B1 HRP970569 B1 HR P970569B1
Authority
HR
Croatia
Prior art keywords
fharmaceutical
compositions
fharmaceutical compositions
Prior art date
Application number
HR970569A
Other languages
English (en)
Inventor
Gary Wayne Goodson
Allen Wayne Wood
Katherine Jeannette Ford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HRP970569A2 publication Critical patent/HRP970569A2/xx
Publication of HRP970569B1 publication Critical patent/HRP970569B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HR970569A 1996-10-31 1997-10-24 Fharmaceutical compositions HRP970569B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
HRP970569A2 HRP970569A2 (en) 1998-08-31
HRP970569B1 true HRP970569B1 (en) 2004-10-31

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970569A HRP970569B1 (en) 1996-10-31 1997-10-24 Fharmaceutical compositions

Country Status (44)

Country Link
EP (1) EP0941100B1 (es)
JP (1) JP2001502718A (es)
KR (1) KR100551652B1 (es)
AP (1) AP1067A (es)
AR (1) AR009135A1 (es)
AT (1) ATE241364T1 (es)
AU (1) AU736607B2 (es)
BG (1) BG64541B1 (es)
BR (1) BR9712614A (es)
CA (1) CA2270174A1 (es)
CO (1) CO4930269A1 (es)
CY (1) CY2485B1 (es)
CZ (1) CZ296080B6 (es)
DE (1) DE69722433T2 (es)
DK (1) DK0941100T3 (es)
EA (1) EA002437B1 (es)
EE (1) EE03806B1 (es)
ES (1) ES2200204T3 (es)
GB (1) GB9622681D0 (es)
GE (1) GEP20022735B (es)
GT (1) GT199700116A (es)
HK (1) HK1020880A1 (es)
HR (1) HRP970569B1 (es)
HU (1) HU224969B1 (es)
ID (1) ID18698A (es)
IL (1) IL129422A0 (es)
IS (1) IS5024A (es)
MY (1) MY119513A (es)
NO (1) NO317163B1 (es)
NZ (1) NZ335153A (es)
OA (1) OA11038A (es)
PA (1) PA8441101A1 (es)
PE (1) PE10099A1 (es)
PL (1) PL190349B1 (es)
PT (1) PT941100E (es)
SI (1) SI0941100T1 (es)
SK (1) SK284286B6 (es)
SV (1) SV1997000090A (es)
TR (1) TR199900950T2 (es)
UA (1) UA64725C2 (es)
UY (1) UY24766A1 (es)
WO (1) WO1998018477A2 (es)
YU (1) YU19999A (es)
ZA (1) ZA979726B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
DE60313657T2 (de) * 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN104203244A (zh) 2012-03-05 2014-12-10 希普拉有限公司 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物
WO2014130553A2 (en) * 2013-02-20 2014-08-28 Abbvie Inc. Tablet dosage forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CO4930269A1 (es) 2000-06-27
SV1997000090A (es) 1998-10-07
IS5024A (is) 1999-04-09
NO992091D0 (no) 1999-04-29
EE03806B1 (et) 2002-08-15
BR9712614A (pt) 1999-10-26
AU5314298A (en) 1998-05-22
EP0941100B1 (en) 2003-05-28
TR199900950T2 (xx) 1999-07-21
BG64541B1 (bg) 2005-07-29
ZA979726B (en) 1999-04-29
EP0941100A2 (en) 1999-09-15
WO1998018477A2 (en) 1998-05-07
PL190349B1 (pl) 2005-11-30
PE10099A1 (es) 1999-03-02
NO992091L (no) 1999-06-29
EA199900345A1 (ru) 2000-02-28
AP1067A (en) 2002-05-01
CZ155799A3 (cs) 1999-10-13
CA2270174A1 (en) 1998-05-07
AP9901519A0 (en) 1999-06-30
UY24766A1 (es) 2000-12-29
ES2200204T3 (es) 2004-03-01
BG103435A (en) 2000-04-28
CY2485B1 (en) 2005-06-03
JP2001502718A (ja) 2001-02-27
IL129422A0 (en) 2000-02-17
PL333143A1 (en) 1999-11-22
CZ296080B6 (cs) 2006-01-11
UA64725C2 (uk) 2004-03-15
ID18698A (id) 1998-04-30
OA11038A (en) 2002-02-06
AU736607B2 (en) 2001-08-02
GB9622681D0 (en) 1997-01-08
KR20000052893A (ko) 2000-08-25
KR100551652B1 (ko) 2006-02-13
MY119513A (en) 2005-06-30
SK57599A3 (en) 2000-06-12
DE69722433D1 (de) 2003-07-03
ATE241364T1 (de) 2003-06-15
WO1998018477A3 (en) 1998-06-18
NZ335153A (en) 2001-04-27
DE69722433T2 (de) 2004-04-08
NO317163B1 (no) 2004-08-30
GEP20022735B (en) 2002-07-25
AR009135A1 (es) 2000-03-08
SI0941100T1 (en) 2003-12-31
EA002437B1 (ru) 2002-04-25
DK0941100T3 (da) 2003-09-01
HUP0000344A3 (en) 2002-04-29
SK284286B6 (sk) 2005-01-03
EE9900175A (et) 1999-12-15
GT199700116A (es) 1999-04-22
HU224969B1 (en) 2006-04-28
HUP0000344A2 (hu) 2001-05-28
HRP970569A2 (en) 1998-08-31
HK1020880A1 (en) 2000-05-26
PA8441101A1 (es) 2000-05-24
PT941100E (pt) 2003-10-31
YU19999A (sh) 2000-10-30

Similar Documents

Publication Publication Date Title
GB9600426D0 (en) Compositions
PL332118A1 (en) Remineralisable compositions
IL128718A0 (en) Naaldase compositions
CY2506B1 (en) Composition
IL130330A0 (en) Endo-ectoparasiticidal compositions
GB9624874D0 (en) Composition
GB9601398D0 (en) Composition
GB9612595D0 (en) Composition
GB9605247D0 (en) Composition
EP0884044A4 (en) HAIR TREATMENT
GB9619074D0 (en) Composition
GB9624540D0 (en) Compositions
GB9600604D0 (en) Composition
GB9620504D0 (en) Compositions
GB9623562D0 (en) Sachet-packaged compositions
GB9602266D0 (en) Composition
HRP970569A2 (en) Fharmaceutical compositions
GB9610966D0 (en) Composition
GB9620503D0 (en) Compositions
GB9611365D0 (en) Compositions
GB9604585D0 (en) Composition
GB9600545D0 (en) Compositions
GB9620533D0 (en) Compositions
GB9619118D0 (en) Compositions
GB9616517D0 (en) Compositions

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051013

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20061025